Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent

McCormick, David L.; Moon, Richard C.

doi:10.1038/bjc.1983.278

Cited by 70 publications

(19 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27) Several researchers have investigated the inhibitory effect of nonsteroidal anti-inflammatory drugs (NSAIDs), i.e., the sulfone metabolite of sulindac, 28) indomethacin, 29) or flurbiprofen, 30) on mammary carcinogenesis in rats. However, Kitagawa and Noguchi found that piroxicam, one of the NSAIDs, had no inhibitory effect on DMBA-induced mammary carcinogenesis.…”

Section: Discussionmentioning

confidence: 99%

Inhibitory Effects of Nabumetone, a Cyclooxygenase‐2 Inhibitor, and Esculetin, a Lipoxygenase Inhibitor, on N‐Methyl‐N‐nitrosourea‐induced Mammary Carcinogenesis in Rats

Matsunaga

Yoshimi²,

Yamada³

et al. 1998

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

We investigated the modifying effects of nabumetone, a relatively selective cyclooxygenase-2 inhibitor, and esculetin, a lipoxygenase inhibitor, on N-methyl-N-nitrosourea(MNU)-induced mammary carcinogenesis in female Sprague-Dawley rats. A total of 124 rats, 6 weeks old, were divided into 6 groups. At 50 days of age, groups 1, 2, and 3 were treated with MNU (50 mg/kg body weight) by subcutaneous injection. From the age of 8 weeks, groups 2 and 4 were given 0.03% nabumetone in the diet and groups 3 and 5 were given 0.03% esculetin in the diet. All rats were necropsied at the termination (25 weeks after the start of experiment). The incidence and multiplicity of neoplasms in group 2 were significantly smaller than those in group 1 (P< < < <0.005 and P< < < <0.001, respectively).The incidence of neoplasms in group 3 was also significantly smaller than that in group 1 (P< < < <0.05). These results indicate that the intake of nabumetone or esculetin during the time corresponding to the post initiation phase has a chemopreventive effect on MNU-induced mammary carcinogenesis in rats.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibitory Effects of Nabumetone, a Cyclooxygenase‐2 Inhibitor, and Esculetin, a Lipoxygenase Inhibitor, on N‐Methyl‐N‐nitrosourea‐induced Mammary Carcinogenesis in Rats

Matsunaga

Yoshimi²,

Yamada³

et al. 1998

Japanese Journal of Cancer Research

View full text Add to dashboard Cite

show abstract

“…The basis for these discrepant observations is unclear. Two additional NSAIDs, flurbiprofen and aspirin, are also capable of reducing carcinogen-induced mammary tumorigenesis (McCormick & Moon 1983, Suzui et al 1997, Mori et al 1999, although piroxicam was not found to be effective in one study (Kitagawa & Noguchi 1994). Two recent studies evaluated the effects of selective COX-2 inhibitors on mammary tumorigenesis.…”

Section: Pharmacological Studies In Rat Breast Cancer Modelsmentioning

confidence: 99%

Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.

Howe

Subbaramaiah

Brown

et al. 2001

Endocrine-Related Cancer

292

218

View full text Add to dashboard Cite

Cyclooxygenase-2 (COX-2), an inducible prostaglandin synthase, is normally expressed in parts of the kidney and brain. Aberrant COX-2 expression was first reported in colorectal carcinomas and adenomas, and has now been detected in various human cancers, including those of the breast. Strikingly, COX-2 overexpression in murine mammary gland is sufficient to cause tumour formation. To date, the role of COX-2 in tumorigenesis has been most intensively studied in the colon. Thus, the relationship between COX-2 and neoplasia can best be illustrated with reference to intestinal tumorigenesis. Here we consider the potential utility of selective COX-2 inhibitors for the prevention and treatment of breast cancer. Data for cancers of the colon and breast are compared where possible. In addition, the mechanisms by which COX-2 is upregulated in cancers and contributes to tumorigenesis are discussed. Importantly, several recent studies of mammary tumorigenesis in animal models have found selective COX-2 inhibitors to be effective in the prevention and treatment of breast cancer. Clinical trials will be needed to determine whether COX-2 inhibition represents a useful approach to preventing or treating human breast cancer.

show abstract

“…63 Expression in breast cancer has been reported in 36% to 79%. [64][65][66] The production of PG-E 2 in this tumor seems to be a potent angiogenic switch. 67 COX-2 expression in breast cancer has also been identified as a negative factor for disease-free survival and is correlated with hormone receptor status, expression of HER-2/neu, stage of disease, and lymph node status.…”

Section: Dommels Et Almentioning

confidence: 99%

Cyclooxygenase in the Treatment of Glioma: Its Complex Role in Signal Transduction

New

2004

Cancer Control

View full text Add to dashboard Cite

Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal antiinflammatory agent

Cited by 70 publications

References 13 publications

Inhibitory Effects of Nabumetone, a Cyclooxygenase‐2 Inhibitor, and Esculetin, a Lipoxygenase Inhibitor, on N‐Methyl‐N‐nitrosourea‐induced Mammary Carcinogenesis in Rats

Inhibitory Effects of Nabumetone, a Cyclooxygenase‐2 Inhibitor, and Esculetin, a Lipoxygenase Inhibitor, on N‐Methyl‐N‐nitrosourea‐induced Mammary Carcinogenesis in Rats

Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.

Cyclooxygenase in the Treatment of Glioma: Its Complex Role in Signal Transduction

Contact Info

Product

Resources

About